GlassScriptPhysician profile
Mohammed O Ahmed
NPI 1235153396
$2,296.89
in general payments reported to CMS, 2019-2025
23 companies · $790 in 2025
The $790 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $130 · 2022: $412 · 2023: $344 · 2024: $621 · 2025: $790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,755.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,754.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $513.39 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $402.78 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $247.28 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $215.20 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $129.15 | 2023-2025 | Farxiga, Airsupra |
| Astellas Pharma US INC | $128.06 | 2023-2025 | Veozah |
| Abbott Laboratories | $117.53 | 2024-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.76 | 2024-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $58.20 | 2025 | |
| Corcept Therapeutics | $55.61 | 2024 | Korlym |
| Amgen INC. | $41.48 | 2021-2024 | Repatha |
| Phathom Pharmaceuticals, INC. | $38.81 | 2025 | Voquezna |
| Idorsia Pharmaceuticals US INC | $34.29 | 2023 | Quviviq |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $32.37 | 2022 | |
| Averitas Pharma INC. | $24.69 | 2024 | Qutenza |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $23.52 | 2022 | |
| Novartis Pharmaceuticals Corporation | $21.93 | 2022 | |
| Esperion Therapeutics, INC. | $21.63 | 2021 | |
| Antares Pharma, INC. | $18.71 | 2025 | Xyosted |
| Genentech USA, INC. | $18.36 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $17.06 | 2022 | |
| Boston Scientific Corporation | $16.82 | 2023 | |
| Insulet Corporation | $12.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.